199 related articles for article (PubMed ID: 29507054)
21. Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death.
Xu X; Eshima S; Kato S; Fisher DE; Sakurai H; Hayakawa Y; Yokoyama S
Mol Cancer Ther; 2020 Feb; 19(2):627-636. PubMed ID: 31744894
[TBL] [Abstract][Full Text] [Related]
22. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
[TBL] [Abstract][Full Text] [Related]
23. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
24. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
25. Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Li M; Liu D; Lee D; Kapoor S; Gibson-Corley KN; Quinn TP; Sagastume EA; Mott SL; Walsh SA; Acevedo MR; Johnson FL; Schultz MK
Mol Pharm; 2019 Sep; 16(9):3904-3915. PubMed ID: 31318566
[TBL] [Abstract][Full Text] [Related]
26. High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.
Lyman SK; Crawley SC; Gong R; Adamkewicz JI; McGrath G; Chew JY; Choi J; Holst CR; Goon LH; Detmer SA; Vaclavikova J; Gerritsen ME; Blake RA
PLoS One; 2011 Mar; 6(3):e17692. PubMed ID: 21408192
[TBL] [Abstract][Full Text] [Related]
27. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
28. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
29. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
30. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Sabbah M; Krayem M; Najem A; Sales F; Miller W; Del Rincon S; Awada A; Ghanem GE; Journe F
Mol Cancer Res; 2021 Jul; 19(7):1221-1233. PubMed ID: 33741716
[TBL] [Abstract][Full Text] [Related]
32. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Smalley KS; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Mol Cancer Ther; 2008 Sep; 7(9):2876-83. PubMed ID: 18790768
[TBL] [Abstract][Full Text] [Related]
33. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
34. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
35. Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis.
Qin M; Xin Y; Bian Y; Yang X; Xi T; Xiong J
Cells; 2022 Jan; 11(2):. PubMed ID: 35053380
[TBL] [Abstract][Full Text] [Related]
36. MITF suppression by CH5552074 inhibits cell growth in melanoma cells.
Aida S; Sonobe Y; Yuhki M; Sakata K; Fujii T; Sakamoto H; Mizuno T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1187-1193. PubMed ID: 28447210
[TBL] [Abstract][Full Text] [Related]
37. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
38. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF
Hartman ML; Czyz M
Arch Dermatol Res; 2020 Jul; 312(5):385-392. PubMed ID: 31624899
[TBL] [Abstract][Full Text] [Related]
39. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.
Takano K; Munehira Y; Hatanaka M; Murakami R; Shibata Y; Shida T; Takeuchi K; Takechi S; Tabata T; Shimada T; Kishikawa S; Matsui Y; Ubukata O; Seki T; Kaneta Y
Mol Cancer Ther; 2023 Mar; 22(3):317-332. PubMed ID: 36622773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
